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Abstract: 
 
      Folate receptors play an important role in drug delivery systems as they are known to 
increase the potency and reduce toxicity of many cancer therapies. Folate receptors are present in 
abundance on cancerous tissues more so than on non-cancerous tissues. Folate binds to a variety 
of drugs that include chemotherapeutic agents, liposomes, radio-imaging agents, 
immunotherapeutic drugs and the like. Folate has been researched and used over the past decade 
as it is inexpensive and binds to the folate receptors with high affinity when compared to 
monoclonal antibodies1. Nuclear imaging by SPECT and PET has interested many researchers. 
Other processes include MRI and optical imaging. 99mTc-EC20 is one of the most promising 
radiopharmaceutical used in the imaging of tumor cells. It is safe and when a clinical trial was 
performed on 155 patients, 68% of them showed 99mTc-EC20 uptake by their tumors2.  This has 
also been used for Atherosclerosis which is used for imaging activated macrophages. 64Cu has 
also been used in producing radiopharmaceuticals where is has been radiolabelled with TETA-
SCK and TETA-SCK-folate conjugates and administered intravenously to get accumulation in 
solid tumors. The research showed that uptake of these conjugates was tumor size dependent and 
the non-folate conjugates were seen more in the blood than the folate conjugates. 
 
Introduction 
Folate: 
      Folate is a general term used to describe the derivatives of pteroic acid that possess vitamin 
properties in the human body. Folate is reduced metabolite tetrahydrofolate (THF) which acts as 
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a carrier of one-carbon units in various biochemical reactions. Folic acid has commonly used  
names such as Folate, Vitamin B Complex, and Pteroyl L – glutamic acid. Others include Acide 
folique, vit b9, tertrahydrofolate, dihydrofolate, folacin, acido folico, 5’–methyl tetra 
hydrofolate, L-methylfolate3. 
      Folic acid is a water soluble vitamin B. Naturally available folic acid is found in leafy 
vegetables like lettuce, spinach, broccoli, and in fruits like bananas, water melons and lemons, 
beetroot, okra, mushrooms, yeasts, meat like beef liver and kidney. Synthetic folic acid is an 
orange-yellow, tasteless, microcrystalline powder. It darkens when heated above 250˚C which is 
followed by charring. Folic acid is comprised of a bicyclic pterin moiety attached by a methylene 
bridge to p-amino benzoic acid which is attached through α- peptide bond to a single molecule of 
L- glutamic acid. 
      Deficiency of folate leads to inadequate DNA replication and impaired cell division, 
especially in the hemopoietic tissue of the bone marrow and epithelial cells of the GIT. Folic 
acid is used for folic acid deficiency i.e. treating the low blood levels of folic acids. This is good 
for anemic conditions, inability of the bowel to absorb nutrients, kidney dialysis, ulcerative 
colitis, and liver diseases. Folic acid is very important for pregnant women as they have an 
increased metabolic demand for folate. Folate intake helps in preventing miscarriage and neural 
tube defects. Under federal law enacted in 1988, folic acid must be added in bread, cereal, bakery 
items etc. Folate is considered to have low acute and chronic toxicity for humans. The dose 
ranges from 250 to 1000 mcg. Unless directed by a health care professional, more than 400 mcg 
is not to be taken by adults. Folic acid may cause side effects like itching, skin rash, difficulty in 
breathing, redness etc3-10.  
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Mechanism of folic acid intake and role of folate receptors: 
      Folates are lipophobic in nature and play an important role in many biochemical processes in 
the body like purine synthesis, conversion of serine to glycine, production of precursors for DNA 
synthesis and its repair, and thymide synthesis. Folates traverse minimally through biological 
membrane by simple diffusion Folate needed for these processes are acquired by two 
mechanisms. 
1) A transmembrane transporter called Reduced folate carrier (RFC). It is a protein with 
12 membrane-spanning domains which transports reduced folates like N5 – 
methytetrahydrofolate (MTF). RFC is present in tissues of the border-membrane of 
the colon, duodenum, ileum and jejunum. It is also present in hepatocytes, choroid 
plexus and retinal epithelium (RPE) of the eye. RFC is also found in serum and has 
much lower affinity to folic acid (See Figure 8). 
2)  The other folate uptake system uses the GPI (Glycosylphatidylinositol) anchored 
protein known as Folate receptor (FR) which transports the folates through fluid-
phase endocytosis.  High affinity is needed for the receptor to bind to its ligands. A kd 
of approx. 0.4nmol/L is needed for folic acid. Although there are three isoforms for 
FR, only FR-α is physiologically relevant. These three isoforms are found in normal 
differential epithelial cells like those found in the placenta, kidney and lungs11-15.  
      Vitamin folic acid is used as a molecular Trojan horse for selectively delivering the probes 
that are attached to the cancer cells. The radioactive probe is linked to folic acid through 
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glutamate moiety, whereas pteroate moiety is used for FR binding on the cancer cells as shown 
in figure 6. 
Stability of folate: 
      As folate is water soluble, it is often lost when blanching vegetables. This loss can be due to 
both thermal degradation and leaching. Steam blanching and microwave blanching cause less 
folate  destruction because of the absence of leaching by water. Polyglutamyl folates, on the 
other hand, are large electronegative molecules which have to be broken down to monoglutamate 
forms in order to be absorbed into the cells. The proteases in saliva, gastric juices and pancreatic 
secretions are not able to convert the Polyglutamyl folates to monoglutamate forms. However, it 
can be readily converted by two folate conjugase which are found in jejunal tissue fractions,  
brush-border exopeptidase and in intracellular endopeptidase. The small intestine fully absorbs 
the monoglutamyl folate and absorption is greater in jejunum than in ileum. When the food is 
ingested in the body the vitamin travels in the plasma as monoglutamyl folate in the 
concentration of 10 to 35 nM. It is carried forward in plasma as free folate or loosely bound to 
plasma proteins like albumin. Ten to 20% of monoglutamyl folate is taken by the liver from the 
portal blood in the first pass, and the remaining is taken by the extrahepatic tissues. The liver 
plays a major role in maintaining folate hemostasis where it stores up to 50 % of the total folate 
present in the body16-19. 
 
 
Use of folate as a targeting vehicle: 
      The folate receptor which is a high folate binding protein is overexpressed in a wide variety 
of human tumor cells as contrasted to normal cells. It is present in high concentrations in cancers 
of  the ovary, mammalian gland, colon, lung, throat, nose, prostrate and other organs. As folate is 
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needed to maintain healthy chromosomes and to perform cell division, the normal cells take in 
only the purest form of the molecule and reject the rest. The tumor cells on the other hand need 
folate in abundant quantities so that cell division can be stimulated. Hence, the folate receptors 
can gorge them in abundance20. 
      The carboxyl group on the folate molecule is linked through a covalent bond to other 
molecules and the folate binds to the molecules more tightly than typical monoclonal antibodies. 
Because of the chemical structure, folates are more stable and are simple to use.  The main 
advantage of using folate as a vehicle, is its size. It is almost 0.3% the weight of an antibody and 
has a molecular weight of 441. Folates are highly tumor specific and also conveniently available. 
 
Discovery of a method that exploits folate receptor endocytosis: 
      Folate-receptor-mediated drug targeting process was first discovered accidentally. Mark 
Horn, a former graduate student, was researching receptor-mediated endocytosis in the plant 
kingdom. For the internalization of the elicitors, he linked them to biotin and followed their 
endocytosis with fluorescent streptavidin. Receptor-mediated endocytosis took place in plant 
cells with biotinylated elicitors. Also when biotin was linked to animal proteins the same 
observation was made. Other research tested whether vitamins too could be exploited to mediate 
the delivery of macromolecules into animal cells. Biotin-mediated internalization was 
demonstrated in some animal cells and further studies revealed that even riboflavin transported 
proteins into a few types of animal cells. Christopher Leamon, a former graduate student, 
observed that folic acid can deliver tethered proteins into cultured animal cells.  
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      In 1991, Philip S.Low and Christopher P.Leamon from Purdue University discovered that 
many cells have an ability to internalize folate-conjugated macromolecules by a folate-receptor 
mediated mechanism. Proteins like IgG, serum albumin, folate conjugated ribonuclease and 
horseradish peroxidase were treated to enter KB cells. The researchers observed that folate 
proteins which were fluorescent labeled were seen to bind and enter the KB cells, whereas 
proteins that were not bound to folate did not enter the cells (Figure 2). Radiolabelled proteins 
that were conjugated with folate were difficult to be removed from the cells completely by acid-
wash saline, whereas controls that lacked folate were easily removed by simple washing with 
PBS. The data obtained from the experiments revealed that folate-conjugates are internalized in a 
non-destructive manner and macromolecules that were bound to folates remained in an active 
state. The data also supported the idea that folate internalization into KB cells follows a 
nonlysozomal pathway1.  
 
99mTc-EC20 - A folate-derivatized radiopharmaceutical: (A SPECT tracer) 
      Atherosclerosis is a leading cause of death in many countries. The word is obtained from the 
Greek words athere which means gruel and skleros which means hard. It is a type of 
arteriosclerosis, where plaque deposits are formed in the interior of the arteries. Many radio 
imaging methods have been employed to reduce the risk of cardiovascular events by early 
detection. Few of those methods include 18F-FDG which measures the sites with increased 
metabolic activity, 99mTc-labeled anti-lectin like oxidized low density lipoprotein receptor 1 
antibody, 99mTc-annexin A5 which exposes regions of apoptosis and thrombosis.  In a research 
conducted by Phillip.S.Low and associates from Purdue University, used 99mTc-EC20 – a folate 
targeted chelate of 99mTc, which was used for the imaging of activated macrophages for 
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atherosclerosis. ApoE -/- mice were raised on both normal and high fat diets. By maintaining the 
mice at high fatty western diet, atherosclerosis was accelerated. Uptake of 99mTc-EC20 was diet 
dependent as the mice maintained on a western diet showed more accumulation of 99mTc-EC20. 
When the mice on the western diet were compared to the mice fed on a low fat diet, the signal 
intensity of 99mTc-EC20 in aortocardiac region was increased upto 70%. It was also observed that 
uptake of 99mTc-EC20 was FR-mediated when the mice on western diet were pre-injected with 
100- fold excess of free folic acid ( See Figure 3). 
 
      18F-FDG has been used mostly for imaging atherosclerosis. It accumulates in metabolizing 
cells, even those regions which are not linked with atherosclerosis. 99mTc-EC20 on the other 
hand, focuses on sites that are abundant in activated macrophages. This helps in reducing 
misinterpretation of results21.  
 
Folate conjugated shell cross-linked nanoparticles (SCK’s): 
      Nanoparticles used for drug delivery and imaging of tumors have been a good challenge. 
64Cu has been used widely for the production of radiopharmaceuticals because of its radioactive 
decay with β+ and β- emission. Professors and students from the Washington University of 
Medicine and University of Texas Southwestern Medical Center conducted a research on 64Cu. 
TETA-SCK and TETA-SCK-folate were radiolabeled with 64Cu and administered intravenously 
to obtain accumulation in solid tumors and were driven by the EPR effect. SCK’s can be 
functionalized with different variety of ligands; prodrugs to have a broader targeting approach. 
Female mice with KB tumor cell xenografts were used in the investigation. The mice were kept 
on diet depleted of folate for three weeks before and also during the experiments to achieve 
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plasma folate levels in a range that is common for humans. Excess folic acid was administered to 
the mice first one day before and again one hour before the experiment was conducted in order to 
evaluate the effects of competitive block of FR on SCK tumor uptake. Folated SCK’s were 
absorbed more by the liver than were the non-folated ones, and because of this, the blood 
retention property was seen more by the non-folated conjugates.  
      It was already known that the folate-conjugated nanoparticles and liposomes do not have 
proper selectivity for solid tumors. This is due to passive extravasation from the permeable 
tumor blood vessels which is known as EPR effect. This research has not only shown similar 
results but also suggested the FR-specific interaction of folate-SCK’s in small tumors. Hence, 
there is a great deal of variability in tumor uptake depending on the size of the tumor; 
furthermore, radio labeled SKC’s can be used for imaging and treating tumors at early stages22,23.  
 
111In-DTPA folate: 
      The folate receptors are overexpressed in neoplastic regions like the ovary, cervical, breast, 
renal and others.  The folate- binding protein is overexpressed in ovaries. Studies show that this 
receptor system is targeted in vivo and in vitro by folate-chelate conjugates, 111In-DTPA- folate 
being one of the main conjugates. In figure 5, 111In-DTPA-folate whole body scintigraphic 
images of a healthy volunteer and an ovarian cancer patient are shown. It is observed that the 
conjugate is accumulated in the malignant tissues and kidneys only. 111In-DTPA- folate has been 
used widely in the clinical imaging of tumors as it has less clearing time from FR- negative 
tissues. In a study to evaluate the ability of 111In-DTPA-folate, four groups of mice were used for 
the study. Three out of four groups received 111In-DTPA-folate conjugate and one group that 
received the conjugate also received an IV dose of folic acid. For competitive displacement of 
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111In-DTPA-folate radiotracer, one group of mice receiving the conjugate also received a chase 
dose of folic acid 3 hours later. The fourth group received unconjugated 111In-DTPA, and the 
fifth group received 111In-citrate. 111In-DTPA-folate was significantly concentrated in KB tumor 
cells with tumor uptake of 1.0% ± 0.5% of the injected dose (3.1% ± 0.6% ID/g) at four hours 
post injection (Figure 11). The results demonstrated that 111In-DTPA-folate radiopharmaceutical 
may be useful in humans for noninvasive imaging of folate receptors-positive tumors. The mice 
bearing the folate receptor-positive tumor KB cells, kidneys, tumors are the only areas that 
retained receptor targeted 111In radiolabel. Figure 5 represents the scintigraphic images of a 
healthy volunteer and a patient with ovary cancer2,24,25. 
 
Conclusion: 
      As folate has a wide range of advantages that include its cost, tumor specificity, and size, it is 
of great interest to researchers. Folate receptors, which are abundantly found on cancer cells will 
help in developing drugs and also for imaging purposes for detecting tumors. 111In-DTPA-folate  
has less clearing time from FR- negative tissues. Hence, it is widely used in clinical imaging of 
tumors and is in clinical trials. Radiolabeled SCK’s can be used for imaging and treating tumors 
at early stages. For imaging Atherosclerosis, 99mTc-EC20 focuses on sites that are abundant in 
activation macrophages unlike 18F-FDG which also gets accumulated in cells not linked with 
Atherosclerosis. Hence, misinterpretation of results are reduced. 99mTc-EC20 is a powerful 
radiotracer and gives clear images of the tumors. 
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Figure-1: Structure of folic acid 
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Figure 2: Uptake of fluorescent folate-labeled proteins by KB cells. 
A,C,E,G represent Phase-contrast micrographs of KB cells incubated with bovine IgG-FITC-
folate for 5,30,60,360 min respectively. B,D,F and H are their corresponding fluorescent 
micrographs. I and K are phase- contrast micrographs showing KB cells that were incubated for 
5 and 360 min respectively with bovine IgG labeled with FITC to the same extent but lacking 
conjugated folate. J and L are their corresponding fluorescent micrographs. M is confocal image 
of a single KB cell incubated for 30 min with RNase A- RITC-folate. (Leamon, Low, Proc Natl 
Acad Sci U S A, July 1 1991) 
 
 
 
 
Figure 3: 99mTc-EC20 targets aortas of apoE2/2 mice and can be used as imaging agent for 
atherosclerosis. ApoE2/2 mice were fed either normal or Western diet for 25 wk and then 
injected intraperitoneally with either  99mTc-EC20 or 99mTc-EC20 plus 100-fold excess free folic 
acid. Radioimages were obtained on Kodak Imaging Station (A) (n 5 10), and regions of interest 
was quantitatively analyzed using instrument software (B) (n 5 10). Mice were then euthanized, 
and excised aortas were analyzed for radioactivity by g-counting (C; n 5 5). During imaging, 5-
mm lead shields were used to cover abdomens to avoid interference from 99mTc-EC20 uptake in 
kidneys and bladder. Data in C are presented as mean +/- SD. *P< 0.05.  FA= folic acid. 
(Wilfredo Ayala-L´opez, Wei Xia, Bindu Varghese and Philip S. Low,  J Nucl Med 2010)14. 
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Figure 4: Formation of 99mTc-EC20 or 99mTc-EC53  
 
 
Figure-5: 111In-DTPA-folate whole body scintigraphic images of a healthy volunteer and an 
ovarian cancer patient. Uptake in the cancer patient is seen in both the malignant tissue and 
kidneys, whereas only kidney uptake is observed in the healthy individual. Image reproduced 
with permission from Endocyte, Inc.1  
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Figure 6: Principle of FR-targeted nuclear imaging. (Muller, Schibli, Journal of Nuclear 
Medicine, Vol 52, No1, Jan 2011)2  
 
 
                       
Figure 7: a) Folate receptor on normal cells              b) Folate receptors on malignant cells. 
                                                                                              
 
                                                                                               
  
Figure-8: Uptake of folate conjugates
No.1, Jan 2008) 
 
Figure 9: SPECT/CT images of female mice bearing human ovarian IGROV
a) After injecting 111ln-DTPA
b) Injected in combination with predosed 
(Muller, Schibli, Journal of Nuclear Medicine. Vol. 52, No 1, Jan 2011)
 
 
 
 (Low, Henne, Accounts of Chemical Research. Vol. 41, 
-1 xenografts 
-folate alone 4 hrs later 
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Figure 10: Structure of 111In-DTPA-folate conjugate. 
 
 
 
Figure 11: Tumor uptake of 111In-DTPA folate 111In-DTPA and 111In-citrate mice with folate-
receptor-positive KB cell tumors. Each column represents data from one animal. The mean 
tumor uptake (+/- sd) is shown above the data for each group of animals. (Mathias, Wang, 
Waters, Turek, Low, Green, The journal of Nuclear Medicine, Vol 39, No 9, Sep 1998). 
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